( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Elagolix Treatment for Endometriosis-Associated Pain
This Phase 2 study evaluated the safety and efficacy of elagolix for treating  endometriosis-associated pain . A total of 155 women with laparoscopically confirmed endometriosis were r and omized to placebo , elagolix 150 mg , or elagolix 250 mg once daily for 12 weeks . Placebo patients were rer and omized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks ; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12 . Monthly mean ( st and ard error of the mean ) reductions were greater with elagolix versus placebo ( −1.19 ± 0.18 , −1.25 ± 0.18 , and −0.88 ± 0.18 for elagolix 150 mg , 250 mg , and placebo , respectively ) ; differences were not statistically significant . Monthly mean dysmenorrhea and nonmenstrual pelvic pain scores were reduced with elagolix , with significant differences for dysmenorrhea at weeks 8 and 12 versus placebo ( P < .05 ) . Minimal bone mineral density changes were observed with elagolix treatment . In women with endometriosis-associated pain  , elagolix demonstrated an acceptable efficacy and safety profile in this Phase 2 study
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .